JP4399265B2 - 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 - Google Patents

3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 Download PDF

Info

Publication number
JP4399265B2
JP4399265B2 JP2003556391A JP2003556391A JP4399265B2 JP 4399265 B2 JP4399265 B2 JP 4399265B2 JP 2003556391 A JP2003556391 A JP 2003556391A JP 2003556391 A JP2003556391 A JP 2003556391A JP 4399265 B2 JP4399265 B2 JP 4399265B2
Authority
JP
Japan
Prior art keywords
phenyl
arh
compound
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003556391A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517675A5 (cg-RX-API-DMAC7.html
JP2005517675A (ja
Inventor
ドライスデール,マーティン,ジェームス
ディモック,ブライアン,ウィリアム
バリル−アロンソ,グザヴィエ
ワークマン,ポール
パール,ローレンス,ハリス
プロドロモウ,クリソストモス
マクドナルド,エドワード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Institute of Cancer Research: Royal Cancer Hospital
Vernalis Cambridge Ltd
Cancer Research Technology Ltd
Original Assignee
The Institute of Cancer Research: Royal Cancer Hospital
Vernalis Cambridge Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130733A external-priority patent/GB0130733D0/en
Priority claimed from GB0225688A external-priority patent/GB0225688D0/en
Application filed by The Institute of Cancer Research: Royal Cancer Hospital, Vernalis Cambridge Ltd, Cancer Research Technology Ltd filed Critical The Institute of Cancer Research: Royal Cancer Hospital
Publication of JP2005517675A publication Critical patent/JP2005517675A/ja
Publication of JP2005517675A5 publication Critical patent/JP2005517675A5/ja
Application granted granted Critical
Publication of JP4399265B2 publication Critical patent/JP4399265B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2003556391A 2001-12-21 2002-12-19 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用 Expired - Fee Related JP4399265B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0130733A GB0130733D0 (en) 2001-12-21 2001-12-21 Therapeutic compounds and their use in therapy
GB0225688A GB0225688D0 (en) 2002-11-04 2002-11-04 Therapeutic compounds and their use in therapy
PCT/GB2002/005778 WO2003055860A1 (en) 2001-12-21 2002-12-19 3,4-diarylpyrazoles and their use in the therapy of cancer

Publications (3)

Publication Number Publication Date
JP2005517675A JP2005517675A (ja) 2005-06-16
JP2005517675A5 JP2005517675A5 (cg-RX-API-DMAC7.html) 2006-02-09
JP4399265B2 true JP4399265B2 (ja) 2010-01-13

Family

ID=26246898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003556391A Expired - Fee Related JP4399265B2 (ja) 2001-12-21 2002-12-19 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用

Country Status (7)

Country Link
US (1) US7247734B2 (cg-RX-API-DMAC7.html)
EP (1) EP1456180B1 (cg-RX-API-DMAC7.html)
JP (1) JP4399265B2 (cg-RX-API-DMAC7.html)
AT (1) ATE374753T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002356301A1 (cg-RX-API-DMAC7.html)
DE (1) DE60222804T2 (cg-RX-API-DMAC7.html)
WO (1) WO2003055860A1 (cg-RX-API-DMAC7.html)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519878A (ja) 2001-11-30 2005-07-07 キネテク ファーマシューティカルズ,インコーポレーテッド ヒドラゾノピラゾール誘導体および治療剤としてのその使用
US6770597B2 (en) * 2002-07-17 2004-08-03 Ishihara Sangyo Kaisha, Ltd. Benzohydrazide derivatives as herbicides and desiccant compositions containing them
EP1542997B1 (en) * 2002-07-24 2012-02-29 Dermira (Canada), Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
ATE323702T1 (de) 2002-08-06 2006-05-15 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
US7468445B2 (en) 2002-08-07 2008-12-23 University Of Mississippi Antigiardial agents and use thereof
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
CA2520804A1 (en) 2003-04-03 2004-10-28 Merck & Co., Inc. Biaryl substituted pyrazoles as sodium channel blockers
GB0309637D0 (en) * 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
EP1704856A4 (en) * 2003-12-26 2009-08-19 Kyowa Hakko Kirin Co Ltd PROTEIN INHIBITOR OF THE HSP90 FAMILY
CA2551948A1 (en) * 2004-01-09 2005-07-28 Novartis Ag Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
GB0402518D0 (en) 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
WO2005110963A1 (en) * 2004-05-19 2005-11-24 Cellzome Ag (biphenyl-3-yl)-carboxylic acids and derivatives thereof and their use in therapy
EP1604970A1 (en) * 2004-05-19 2005-12-14 Cellzome Ag 2-(Biphenyl-3-yl)-carboxylic acids of gamma-secretase-modulating activity
DE102004039280A1 (de) * 2004-08-13 2006-02-23 Merck Patent Gmbh 1,5-Diphenyl-pyrazole
CN101023119B (zh) 2004-09-22 2010-05-05 日本化药株式会社 新型嵌段共聚物,胶束制剂以及含胶束制剂为活性组分的抗癌剂
DE102004049078A1 (de) 2004-10-08 2006-04-13 Merck Patent Gmbh Phenylpyrazole
ES2594874T3 (es) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
DE102005007304A1 (de) 2005-02-17 2006-08-24 Merck Patent Gmbh Triazolderivate
JPWO2006088193A1 (ja) * 2005-02-21 2008-07-03 協和醗酵工業株式会社 抗腫瘍剤
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
EP1857446B1 (en) 2005-03-09 2013-05-01 Nippon Kayaku Kabushiki Kaisha Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer
CN101193862B (zh) 2005-04-13 2013-08-21 阿斯特克斯治疗有限公司 羟基苯甲酰胺衍生物和其作为hsp90抑制剂的用途
WO2006122546A1 (de) * 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
FR2885904B1 (fr) * 2005-05-19 2007-07-06 Aventis Pharma Sa Nouveaux derives du fluorene, compositions les contenant et utilisation
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2007021966A1 (en) * 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
CA2618628C (en) 2005-08-18 2014-11-18 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
NL2000351C2 (nl) 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US20070253896A1 (en) * 2006-02-07 2007-11-01 Conforma Therapeutics Corporation 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
CA2652656A1 (en) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
JP5441691B2 (ja) 2006-05-25 2014-03-12 シンタ ファーマシューティカルズ コーポレーション Hsp90活性を調節するトリアゾール化合物
AU2007267803B2 (en) * 2006-05-25 2011-08-25 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited 複合薬剤
EP2080779B1 (en) 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
EP2090607B1 (en) 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of nucleic acid metabolic antagonist
DE102007002715A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
PE20090110A1 (es) 2007-03-01 2009-04-04 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de amina como agentes inhibidores de hsp90
TW200901960A (en) 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US8993608B2 (en) 2007-03-12 2015-03-31 Synta Pharmaceuticals Corp. Method for inhibiting topoisomerase II
BRPI0815042A2 (pt) * 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
WO2009026658A1 (en) * 2007-08-29 2009-03-05 The University Of Sydney Ppar agonists
CA2699794C (en) 2007-09-10 2016-07-19 University Of Massachusetts Mitochondria-targeted anti-tumor agents
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
KR101589582B1 (ko) 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
WO2010001989A1 (ja) * 2008-07-03 2010-01-07 協和発酵キリン株式会社 癌幹細胞及び/または癌前駆細胞の減少剤並びに癌の再発及び/または転移の予防剤
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
EP2151434A1 (en) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
EP2151433A1 (en) 2008-08-05 2010-02-10 Institut Pasteur Alkoxypyrazoles and the process for their preparation
PL2406216T3 (pl) * 2009-03-11 2017-09-29 Bayer Intellectual Property Gmbh Ketoenole podstawione halogenoalkilometylenoksyfenylem
CN102438988B (zh) 2009-04-21 2015-06-24 内尔维阿诺医学科学有限公司 作为hsp90抑制剂的间苯二酚衍生物
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
NZ623069A (en) 2009-08-17 2015-11-27 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2011040421A1 (ja) 2009-09-29 2011-04-07 武田薬品工業株式会社 スクリーニング方法
AR078538A1 (es) 2009-10-07 2011-11-16 Karobio Ab Pirroles e imidazoles sustituidos como ligandos del receptor de estrogenos
AU2011209234B2 (en) * 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
CN102753546A (zh) * 2010-02-17 2012-10-24 日东制药株式会社 新型5-元杂环衍生物及其制备方法
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
JP5938038B2 (ja) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
JP5856069B2 (ja) 2010-11-17 2016-02-09 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
GB201113538D0 (en) 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
JP5711378B2 (ja) 2011-09-11 2015-04-30 日本化薬株式会社 ブロック共重合体の製造方法
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
JP6150813B2 (ja) 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
CN103183640B (zh) * 2011-12-30 2016-04-27 沈阳药科大学 二芳基吡唑类化合物及其制备方法与用途
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
DE102013012685A1 (de) * 2013-07-31 2015-02-05 Johann-Wolfgang-Goethe Universität Frankfurt am Main Arylierte Pyrazolderivate und deren Verwendung als Fluoreszenzfarbstoffe
CN104974091B (zh) * 2014-04-10 2018-01-02 沈阳药科大学 3‑甲基‑1,5‑二芳基吡唑类化合物及其制备方法和用途
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
FR3022244B1 (fr) * 2014-06-17 2016-07-01 Centre Nat De La Rech Scient (Cnrs) Utilisation d'un nouveau compose 3-aryl-4-catechol-pyrrole-n-propanol et ses derives pour le traitement du cancer et des pathologies associees a une angiogenese excessive
JP6760946B2 (ja) * 2015-01-22 2020-09-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Hsp90阻害剤としてのレゾルシノール誘導体
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
WO2019236765A1 (en) * 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Acylated catechin polyphenols and methods of their use for the treatment of cancer
CN109134204B (zh) * 2018-11-16 2022-03-08 棓诺(苏州)新材料有限公司 中间体2-溴-4-氟-5-氯苯酚的合成法
CN110283080A (zh) * 2019-07-05 2019-09-27 山西大学 一种含氟的二苯甲酮衍生物及其制备方法和应用
EP3827825A1 (en) * 2019-11-26 2021-06-02 Wageningen Universiteit Use of 3, 4-diarylpyrazoles as antibacterial agents
US20230348454A1 (en) * 2020-09-14 2023-11-02 Genzyme Corporation Compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease
GB202015187D0 (en) 2020-09-25 2020-11-11 Sentinel Oncology Ltd A pharmaceutical salt
WO2022232259A1 (en) * 2021-04-28 2022-11-03 Cornell University Soluble adenylyl cyclase (sac) inhibitors and uses thereof
WO2023004280A1 (en) * 2021-07-19 2023-01-26 The Board Of Trustees Of The Leland Stanford Junior University Selective pyrazole lrrk2 inhibitors and methods for use thereof
CN120623147B (zh) * 2025-08-01 2025-12-16 广东省科学院动物研究所 吡唑喹啉醚类化合物及其在制备神经保护药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5932576A (en) * 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
DE69935335T2 (de) * 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
AU1199600A (en) 1998-10-02 2000-04-26 Board Of Trustees Of The University Of Illinois, The Estrogen receptor ligands
ATE291020T1 (de) 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
GB0102687D0 (en) * 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
JP2005022972A (ja) * 2001-05-16 2005-01-27 Teikoku Hormone Mfg Co Ltd 4−(4−ピリダジニル)ピラゾール誘導体

Also Published As

Publication number Publication date
AU2002356301A1 (en) 2003-07-15
WO2003055860A1 (en) 2003-07-10
ATE374753T1 (de) 2007-10-15
DE60222804D1 (de) 2007-11-15
JP2005517675A (ja) 2005-06-16
US20050222230A1 (en) 2005-10-06
DE60222804T2 (de) 2008-07-03
US7247734B2 (en) 2007-07-24
EP1456180A1 (en) 2004-09-15
EP1456180B1 (en) 2007-10-03

Similar Documents

Publication Publication Date Title
JP2005517675A (ja) 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用
US10941152B2 (en) Pyrazole compounds as modulators of FSHR and uses thereof
US6291505B1 (en) Estrogen receptor modulators
JP4575779B2 (ja) 癌治療用のhsp90阻害剤としての3−(2−ヒドロキシ−フェニル)−1h−ピラゾール−4−カルボン酸アミド誘導体
TW202210488A (zh) 吡嗪類衍生物及其在抑制shp2中的應用
CN107231802B (zh) 杂环衍生物及其用途
JP4921162B2 (ja) 熱ショックタンパク質の阻害剤としてのイソオキサゾール化合物類
AU2003217393B2 (en) Ansamycins having improved pharmacological and biological properties
JP4528131B2 (ja) ピラゾール化合物
AU2001260504A1 (en) Barbituric acid analogs as therapeutic agents
EA017852B1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EP1065203A2 (en) Heterocyclic compounds as retinoic acid receptor antagonists
US20210009581A1 (en) Ion channel inhibitor compounds for cancer treatment
WO2007029021A1 (en) 1,5-substituted tetrazoles as therapeutic compounds
JP2019532929A (ja) 化合物およびpde4活性剤としてのそれらの使用
Özdemir et al. Evaluation of cytotoxic activity of new benzimidazole-piperazine hybrids against human MCF-7 and A549 cancer cells
KR20250068738A (ko) 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
KR20070045290A (ko) Hsp90의 억제제
US20210024499A1 (en) Oxidized bis(3-indolyl)methanes and uses thereof
EP1416936B1 (en) Thiopyrane-4-ones as dna protein kinase inhibitors
USRE39708E1 (en) Estrogen receptor modulators
CA3099847A1 (en) Mitogen-activated protein kinase kinase 7 inhibitors
JPH05112571A (ja) ピリミジン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090907

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091006

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091026

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121030

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees